Investor Relations

Company Info

AgeX Therapeutics is focused on the development and commercialization of novel therapeutics targeting human aging. We are building upon the foundation of our proprietary technologies such as PureStem® and induced Tissue Regeneration (iTRTM) to develop innovative medicines designed to address some of the largest unsolved problems in aging. Through PureStem® we have the ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging with a high unmet medical need. iTRTM is our revolutionary longevity platform aiming to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body.

Our lead PureStem® derived cell-based therapeutic candidates in development are AGEX-VASC1 and AGEX-BAT1:

  • AGEX-VASC1 is a cell-based therapy in the preclinical stage of development comprised of vascular endothelial progenitor cells for cardiac ischaemia as a lead indication.
  • AGEX-BAT1 is our preclinical cell therapy product candidate of brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II diabetes.

Our lead iTRTM drug-based therapeutic candidate in development is AGEX-iTR1547:
  • AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using our proprietary iTRTM technology.

Latest News

View all news

Latest Presentation

Latest Events

View All Events